$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

$ptn Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000165495424014335 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$0.00	$2.106M
YoY Change		-100.0%	142.16%
Cost Of Revenue			$0.00
YoY Change			-100.0%
Gross Profit			$2.106M
YoY Change			168.91%
Gross Profit Margin			100.0%
Selling, General & Admin		$2.021M	$3.200M
YoY Change		-36.85%	-8.79%
% of Gross Profit			151.96%
Research & Development		$5.744M	$5.015M
YoY Change		14.54%	-16.8%
% of Gross Profit			238.11%
Depreciation & Amortization		$80.79K	$90.00K
YoY Change		-10.23%	50.94%
% of Gross Profit			4.27%
Operating Expenses		$7.765M	$8.215M
YoY Change		-5.48%	-14.63%
Operating Profit		-$7.765M	-$6.109M
YoY Change		27.1%	-30.21%
Interest Expense		$5.940K	$10.88K
YoY Change		-45.41%	13.33%
% of Operating Profit
Other Income/Expense, Net		-$58.96K	$220.5K
YoY Change		-126.74%	-55.66%
Pretax Income		-$7.824M	-$5.890M
YoY Change		32.83%	-28.65%
Income Tax
% Of Pretax Income
Net Earnings		-$7.824M	-$5.888M
YoY Change		32.87%	-28.67%
Net Earnings / Revenue			-279.6%
Basic Earnings Per Share		-$0.39	-$0.43
Diluted Earnings Per Share		-$0.39	-$0.48
COMMON SHARES
Basic Shares Outstanding	19.55M shares	19.55M shares	11.95M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.384M	$5.500M
YoY Change	-56.65%	-74.05%
Cash & Equivalents	$2.384M	$5.525M
Short-Term Investments		$0.00
Other Short-Term Assets	$228.4K	$1.300M
YoY Change	-82.43%	-38.24%
Inventory		$1.598M
Prepaid Expenses
Receivables		$1.349M
Other Receivables		$0.00
Total Short-Term Assets	$2.613M	$9.805M
YoY Change	-73.36%	-62.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$307.6K	$597.6K
YoY Change	-48.53%	-3.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$56.92K	$56.92K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$802.6K	$1.442M
YoY Change	-44.34%	-1.54%
TOTAL ASSETS
Total Short-Term Assets	$2.613M	$9.805M
Total Long-Term Assets	$802.6K	$1.442M
Total Assets	$3.415M	$11.25M
YoY Change	-69.64%	-59.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.949M	$2.270M
YoY Change	73.99%	-39.87%
Accrued Expenses	$4.573M	$7.152M
YoY Change	-36.06%	16.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$18.53K	$100.0K
YoY Change	-81.47%	-2.21%
Total Short-Term Liabilities	$9.862M	$13.61M
YoY Change	-27.54%	-14.2%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$1.239M	$2.027M
YoY Change	-38.88%	-26.01%
Total Long-Term Liabilities	$1.239M	$2.027M
YoY Change	-38.88%	-26.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.862M	$13.61M
Total Long-Term Liabilities	$1.239M	$2.027M
Total Liabilities	$11.10M	$16.14M
YoY Change	-31.21%	-15.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$449.6M	-$421.4M
YoY Change	6.69%	6.34%
Common Stock	$195.5K	$119.5K
YoY Change	63.63%	28.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.686M	-$4.889M
YoY Change
Total Liabilities & Shareholders Equity	$3.415M	$11.25M
YoY Change	-69.64%	-59.31%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$7.824M	-$5.888M
YoY Change	32.87%	-28.67%
Depreciation, Depletion And Amortization	$80.79K	$90.00K
YoY Change	-10.23%	50.94%
Cash From Operating Activities	-$7.016M	-$5.906M
YoY Change	18.79%	23782.55%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$2.990M
YoY Change	-100.0%
Cash From Investing Activities	$0.00	$2.993M
YoY Change	-100.0%	-2219.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$127.0K	$448.9K
YoY Change	-128.28%	-105.23%
NET CHANGE
Cash From Operating Activities	-$7.016M	-$5.906M
Cash From Investing Activities	$0.00	$2.993M
Cash From Financing Activities	-$127.0K	$448.9K
Net Change In Cash	-$7.143M	-$2.465M
YoY Change	189.83%	-71.82%
FREE CASH FLOW
Cash From Operating Activities	-$7.016M	-$5.906M
Capital Expenditures		$0.00
Free Cash Flow		-$5.906M
YoY Change		-5169.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	228435	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	242272	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	2612649	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	9769668	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	307571	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	438123	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	527321	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	usd
CY2024Q3	us-gaap	Assets Assets	3415259	usd
CY2024Q2	us-gaap	Assets Assets	10742266	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	944150	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9861717	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9657681	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19548167	shares
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2384214	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3949028	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4101929	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4185046	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	319520	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	380542	usd
CY2024Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	18527	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	46014	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1001350	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	132447	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	163782	usd
CY2024Q3	us-gaap	Other Long Term Debt OtherLongTermDebt	1106700	usd
CY2024Q2	us-gaap	Other Long Term Debt OtherLongTermDebt	1032300	usd
CY2024Q3	us-gaap	Liabilities Liabilities	11100864	usd
CY2024Q2	us-gaap	Liabilities Liabilities	10853763	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17926640	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	195481	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	179266	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	441709073	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	441475747	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-449590199	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-441766550	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-7685605	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-111497	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3415259	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10742266	usd
CY2023Q3	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	1168144	usd
CY2023Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	263400	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5619090	usd
CY2023Q3	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	4187546	usd
CY2024Q3	ptn	Money Market Accounts And Treasury Bills MoneyMarketAccountsAndTreasuryBills	1974575	usd
CY2024Q3	ptn	Personal Cost PersonalCost	0	usd
CY2024Q3	ptn	Accrued Selling Expenses AccruedSellingExpenses	324640	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	139731	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	201883	usd
CY2024Q2	ptn	Tota Acrrued Liabilities TotaAcrruedLiabilities	4185046	usd
CY2017Q4	ptn	Taxexpenses taxexpenses	82500	usd
CY2017Q4	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	3000000	usd
CY2024Q3	ptn	Prepaid Clinical Study Costs PrepaidClinicalStudyCosts	39823	usd
CY2024Q2	ptn	Prepaid Clinical Study Costs PrepaidClinicalStudyCosts	23926	usd
CY2024Q3	ptn	Prepaid Insurance Premiums PrepaidInsurancePremiums	43956	usd
CY2024Q2	ptn	Prepaid Insurance Premiums PrepaidInsurancePremiums	71097	usd
CY2024Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	144656	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	147248	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	228435	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	242271	usd
CY2024Q3	ptn	Tota Acrrued Liabilities TotaAcrruedLiabilities	4573292	usd
CY2024Q3	ptn	Cost Clinical Study CostClinicalStudy	3761718	usd
CY2024Q2	ptn	Cost Clinical Study CostClinicalStudy	1509797	usd
CY2024Q3	ptn	Other Research Related Expenses OtherResearchRelatedExpenses	159965	usd
CY2024Q2	ptn	Other Research Related Expenses OtherResearchRelatedExpenses	65972	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	187238	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	284215	usd
CY2024Q3	ptn	Accrued Other Long Term Liabilities AccruedOtherLongTermLiabilities	1106700	usd
CY2024Q2	ptn	Accrued Other Long Term Liabilities AccruedOtherLongTermLiabilities	1032300	usd
CY2024Q3	ptn	Retained Earning Accumulated Deficit RetainedEarningAccumulatedDeficit	449590199	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-7823649	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2384214	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9861717	usd
CY2024Q3	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Use of Estimates</em>– The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024Q3	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Credit Risk</em> – Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company. </p>
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11105938	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4519682	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	279700	shares
CY2024Q3	us-gaap	Accounts Receivable Purchase AccountsReceivablePurchase	171000000	usd
CY2024Q3	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	9500000	usd
CY2024Q3	us-gaap	Payments For Purchase Of Other Assets1 PaymentsForPurchaseOfOtherAssets1	2500000	usd
CY2024Q3	ptn	Payments To Sales Based Milestone Payments PaymentsToSalesBasedMilestonePayments	159000000	usd
CY2017Q3	us-gaap	Increase Decrease In Deferred Revenue And Customer Advances And Deposits IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits	4500000	usd
CY2017Q3	us-gaap	Payments For Restructuring PaymentsForRestructuring	5000000	usd
CY2017Q3	ptn	Upfront Payment Of Less UpfrontPaymentOfLess	500000	usd
CY2017Q4	us-gaap	Officers Compensation OfficersCompensation	417500	usd
CY2017Q4	us-gaap	Payments For Restructuring PaymentsForRestructuring	500000	usd
CY2024Q3	ptn	Carrying Value During The Year CarryingValueDuringTheYear	1974575	usd
CY2024Q2	ptn	Accrued Selling Expenses AccruedSellingExpenses	351485	usd
CY2024Q3	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	2661400	usd
CY2024Q3	ptn	Other Liabilities Currents OtherLiabilitiesCurrents	1001350	usd
CY2024Q2	ptn	Other Liabilities Currents OtherLiabilitiesCurrents	944150	usd
CY2024Q3	us-gaap	Cash Available For Distributions CashAvailableForDistributions	100	usd
CY2024Q1	ptn	Description Of Securities Purchase Agreement DescriptionOfSecuritiesPurchaseAgreement	an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the “January 2024 Private Warrants”) to purchase up to 1,831,503 shares of the Company’s common stock (the “January 2024 Private Warrant Shares”) in a concurrent private placement (the “Private Offering” and together with the January 2024 RD Offering, the “January 2024 Offering”). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.46
CY2024Q3	ptn	Gross Proceeds GrossProceeds	10000006	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	9224056	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.12
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0001
CY2023Q4	us-gaap	Costs And Expenses CostsAndExpenses	4573948	usd
CY2024Q3	ptn	Equity Gross Proceeds Shares EquityGrossProceedsShares	217027	shares
CY2024Q3	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	547803	usd
CY2024Q3	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	16434	usd
CY2024Q3	ptn	Equity Expenses Proceeds EquityExpensesProceeds	0	usd
CY2024Q3	ptn	Equity Net Proceeds Proceeds EquityNetProceedsProceeds	531369	usd
CY2024Q3	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Beginning Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance	6.11
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P8Y2M12D
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.92
CY2024Q3	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance	2249102	shares
CY2024Q3	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance	6.12
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
CY2024Q3	ptn	Share Based Compensation Arrangement By Shares Based Payment Award Options Outstanding And Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue	0	usd
CY2024Q3	ptn	Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Number Ending Balance3 A ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A	927524	shares
CY2024Q3	ptn	Share Based Compensation Arrangement By Share Based Payments Award Option Exercisable Weighted Average Exercise Price shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice	10.81
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2024Q3	ptn	Share Based Compensation Arrangement By Shares Based Payment Award Options Outstanding And Outstanding Aggregate Intrinsic Value Exercisable ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable	0	usd
CY2024Q3	ptn	Share Based Compensation Arrangement By Share Based Payment Award Option Expectedtovest Number Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance	1321578	shares
CY2024Q3	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice	2.83
CY2024Q3	ptn	Share Based Compensation Arrangement By Shares Based Payment Award Options Vested And Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue	0	usd
CY2024Q2	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber	1374980	shares
CY2024Q3	ptn	Restricted Stock Vested In Period RestrictedStockVestedInPeriod	-232941	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	2726	shares
CY2024Q3	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber	1139313	shares
CY2024Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000911216
CY2024Q3	dei	Amendment Flag AmendmentFlag	false
CY2024Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19548167	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17926640	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	279700	shares
CY2024Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	7781844	usd
CY2023Q4	us-gaap	Costs And Expenses CostsAndExpenses	9109117	usd
CY2024Q3	dei	Document Type DocumentType	10-Q
CY2024Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q3	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q3	dei	Entity File Number EntityFileNumber	001-15543
CY2024Q3	dei	Entity Registrant Name EntityRegistrantName	PALATIN TECHNOLOGIES, INC.
CY2024Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4078884
CY2024Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	4B Cedar Brook Drive
CY2024Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranbury
CY2024Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2024Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08512
CY2024Q3	dei	City Area Code CityAreaCode	609
CY2024Q3	dei	Local Phone Number LocalPhoneNumber	495‑2200
CY2024Q3	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2024Q3	dei	Trading Symbol TradingSymbol	PTN
CY2024Q3	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2024Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q3	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19548167	shares
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9527396	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	388361	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4573292	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	ptn	Product Revenue Net ProductRevenueNet	0	usd
CY2023Q3	ptn	Product Revenue Net ProductRevenueNet	2105977	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5743754	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5014630	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2020931	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3200244	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	7764685	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	8214874	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7764685	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6108897	usd
CY2024Q3	us-gaap	Investment Income Net InvestmentIncomeNet	78576	usd
CY2023Q3	us-gaap	Investment Income Net InvestmentIncomeNet	71630	usd
CY2024Q3	ptn	Foreign Currency Transaction Loss Gain ForeignCurrencyTransactionLossGain	-131600	usd
CY2023Q3	ptn	Foreign Currency Transaction Loss Gain ForeignCurrencyTransactionLossGain	159750	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	5940	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	10882	usd
CY2024Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	682400	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-58964	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	902898	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-7823649	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5205999	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19845106	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12170699	shares
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-111497	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	349023	usd
CY2024Q3	ptn	Withholding Taxes Related To Restricted Stock Units Amount WithholdingTaxesRelatedToRestrictedStockUnitsAmount	-99482	usd
CY2024Q3	ptn	Shares Released From Abeyance Amount SharesReleasedFromAbeyanceAmount	0	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-7823649	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-7685605	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1979871	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	390336	usd
CY2023Q3	ptn	Withholding Taxes Related To Restricted Stock Units Amount WithholdingTaxesRelatedToRestrictedStockUnitsAmount	-56401	usd
CY2023Q3	ptn	Sale Of Common Stock Net Of Costs Amount SaleOfCommonStockNetOfCostsAmount	531369	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5205999	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-6320566	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-7823649	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-5205999	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	80790	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	87357	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	89198	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	88563	usd
CY2024Q3	ptn	Unrealized Foreign Currency Transaction Loss Gain UnrealizedForeignCurrencyTransactionLossGain	131600	usd
CY2023Q3	ptn	Unrealized Foreign Currency Transaction Loss Gain UnrealizedForeignCurrencyTransactionLossGain	-159750	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	349023	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	390336	usd
CY2024Q3	ptn	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	0	usd
CY2023Q3	ptn	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	-682400	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1567260	usd
CY2024Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13837	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	563548	usd
CY2024Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
CY2023Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1072251	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-152901	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2033887	usd
CY2024Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	388246	usd
CY2023Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	641212	usd
CY2024Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-92357	usd
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-90382	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7016213	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5906393	usd
CY2024Q3	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
CY2023Q3	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2992890	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2992890	usd
CY2024Q3	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	99482	usd
CY2023Q3	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	56401	usd
CY2024Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	531369	usd
CY2024Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27487	usd
CY2023Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	26074	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-126969	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	448894	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7143182	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2464609	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9527396	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7989582	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2384214	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5524973	usd
CY2024Q3	us-gaap	Interest Paid Net InterestPaidNet	5940	usd
CY2023Q3	us-gaap	Interest Paid Net InterestPaidNet	10882	usd
CY2024Q3	ptn	Sales Based Milestone Payments SalesBasedMilestonePayments	159000000	usd
CY2024Q2	ptn	Money Market Accounts And Treasury Bills MoneyMarketAccountsAndTreasuryBills	9089113	usd
CY2024Q2	ptn	Carrying Value During The Year CarryingValueDuringTheYear	9089113	usd
CY2024Q2	ptn	Personal Cost PersonalCost	1771694	usd
CY2023Q4	ptn	Description Of Securities Purchase Agreement DescriptionOfSecuritiesPurchaseAgreement	) 1,325,000 shares of common stock (the “October 2023 Shares”), of the Company and (ii) pre-funded warrants (the “October 2023 Pre-Funded Warrants”) to purchase up to 1,033,491 shares of the Company’s common stock (the “October 2023 Pre-Funded Warrant Shares”). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the “October 2023 Private Warrants”) to purchase up to 2,358,491 shares of the Company’s common stock (the “October 2023 Private Warrant Shares”) in a concurrent private placement (the “October 2023 Private Offering” and together with the October 2023 RD Offering, the “October 2023 Offering”). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023
CY2023Q2	ptn	Description Of Securities Purchase Agreement DescriptionOfSecuritiesPurchaseAgreement	The 2023 Equity Distribution Agreement and related prospectus is limited to sales of up to an aggregate maximum $50.0 million of shares of the Company’s common stock. The Company pays Canaccord 3.0% of the gross proceeds as a commission
CY2024Q3	ptn	Equity Net Proceeds Shares EquityNetProceedsShares	217027	shares
CY2024Q3	ptn	Stock Based Compensation To Stock Options StockBasedCompensationToStockOptions	177734	usd
CY2023Q3	ptn	Stock Based Compensation To Stock Options StockBasedCompensationToStockOptions	205317	usd
CY2024Q3	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Beginning Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance	2263440	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024Q3	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Outstanding Number Ending Balance01 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01	-14338	shares
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y1M6D
CY2024Q3	ptn	Unvested Performance Based Stock Options Granted UnvestedPerformanceBasedStockOptionsGranted	418945	shares
CY2023Q3	ptn	Unvested Performance Based Stock Options Granted UnvestedPerformanceBasedStockOptionsGranted	88911	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	95167	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	60566	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	238838	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	264945	shares
CY2024Q3	ptn	Stock Issued During Period Value Share Based Compensation To Restricted Stock Units StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits	171289	usd
CY2023Q3	ptn	Stock Issued During Period Value Share Based Compensation To Restricted Stock Units StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits	185019	usd
CY2024Q3	ptn	Number Of Outstanding Shares Of Restricted Stock Units NumberOfOutstandingSharesOfRestrictedStockUnits	279700	shares
CY2024Q3	ptn	Unvested Performance Based Stock Options Granted Estricted Stock Units UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits	274549	shares
CY2023Q3	ptn	Unvested Performance Based Stock Options Granted Estricted Stock Units UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits	59842	shares
CY2021	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Rsu ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU	22343	shares
CY2022	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Rsu ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU	40707	shares
CY2023	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Rsu ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU	152432	shares
CY2024	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Rsu ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU	184443	shares
CY2024Q3	ptn	Stock Issued During Period Value Restricted Stock Unitshares StockIssuedDuringPeriodValueRestrictedStockUnitshares	54691	shares

Files In Submission

Name	View Source	Status
0001654954-24-014335-index-headers.html	Edgar Link	pending
0001654954-24-014335-index.html	Edgar Link	pending
0001654954-24-014335.txt	Edgar Link	pending
0001654954-24-014335-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ptn-20240930.xsd	Edgar Link	pending
ptn_10q.htm	Edgar Link	pending
ptn_10qimg15.jpg	Edgar Link	pending
ptn_10qimg17.jpg	Edgar Link	pending
ptn_ex311.htm	Edgar Link	pending
ptn_ex312.htm	Edgar Link	pending
ptn_ex321.htm	Edgar Link	pending
ptn_ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
ptn-20240930_cal.xml	Edgar Link	unprocessable
ptn-20240930_def.xml	Edgar Link	unprocessable
ptn-20240930_lab.xml	Edgar Link	unprocessable
ptn-20240930_pre.xml	Edgar Link	unprocessable
ptn_10q_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

2024 Q4 Form 10-Q Financial Statement

#000165495424014335 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN PALATIN TECHNOLOGIES INC Stock $ptn

2024 Q4 Form 10-Q Financial Statement

#000165495424014335 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn